| abstract |
The present disclosure relates, inter alia, to compositions comprising inhibitors of human complement and the use of the compositions in methods for treating or preventing complement-related disorders. In some embodiments, the inhibitor is chronically administered to the patient. In some embodiments, the inhibitor is administered to the patient in an amount and frequency that maintains systemic complement inhibition and prevents rapid progression. In some embodiments, the composition comprises a human complement component C5 protein or a fragment of that protein, eg, an antibody that binds C5a or C5b, or an antigen-binding fragment thereof. |